Literature DB >> 22511412

Canadian Consensus Conference: The FDA decision on the use of 5ARIs.

Laurence Klotz1, Michael Chetner, Joseph Chin, Tony Finelli, Neil Fleshner, Yves Fradet, Larry Goldenberg, J Curtis Nickel, Robert Siemens, Alan So, Linda Sugar, Alexandre Zlotta, Eric Klein, Howard Parnes, David Penson.   

Abstract

Year:  2012        PMID： 22511412      PMCID： PMC3328559          DOI： 10.5489/cuaj.12058

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

1.  Re: Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.

Authors:  Patrick C Walsh
Journal:  J Urol       Date:  2012-02-14       Impact factor: 7.450

2.  The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

Authors:  Gerald L Andriole; David Bostwick; Otis W Brawley; Leonard Gomella; Michael Marberger; Francesco Montorsi; Curtis Pettaway; Teuvo L J Tammela; Claudio Teloken; Donald Tindall; Stephen J Freedland; Matthew C Somerville; Timothy H Wilson; Ivy Fowler; Ramiro Castro; Roger S Rittmaster
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

Review 3.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

4.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

5.  The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

Authors:  Marc R Theoret; Yang-Min Ning; Jenny J Zhang; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  N Engl J Med       Date:  2011-06-15       Impact factor: 91.245

Review 6.  Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.

Authors:  Yair Lotan; Jeffrey A Cadeddu; J Jack Lee; Claus G Roehrborn; Scott M Lippman
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

7.  Estimated impact of the Prostate Cancer Prevention Trial on population mortality.

Authors:  Joseph M Unger; Ian M Thompson; Michael LeBlanc; John J Crowley; Phyllis J Goodman; Leslie G Ford; Charles A Coltman
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

8.  Delivering prostate cancer prevention messages to the public: how the National Cancer Institute (NCI) effectively spread the word about the Prostate Cancer Prevention Trial (PCPT) results.

Authors:  Kara Smigel Croker; Anne Ryan; Thuy Morzenti; Lynn Cave; Tamara Maze-Gallman; Leslie Ford
Journal:  Urol Oncol       Date:  2004 Jul-Aug       Impact factor: 3.498

9.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245
  10 in total
  5 in total

1.  Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update.

Authors:  J Curtis Nickel; Lorne Aaron; Jack Barkin; Dean Elterman; Mahmoud Nachabé; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2018-10       Impact factor: 1.862

2.  UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.

Authors:  Dean Elterman; Mélanie Aubé-Peterkin; Howard Evans; Hazem Elmansy; Malek Meskawi; Kevin C Zorn; Naeem Bhojani
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

3.  The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.

Authors:  Neerav Monga; Amyn Sayani; Daniel A Rubinger; Timothy H Wilson; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

4.  Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Authors:  Chris Morash; Rovena Tey; Chika Agbassi; Laurence Klotz; Tom McGowan; John Srigley; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

5.  Steroid Hormone Receptors as Potential Mediators of the Clinical Effects of Dutasteride: A Prospective, Randomized, Double-Blind Study.

Authors:  João C C Alonso; Leonardo O Reis; Patrick V Garcia; Ubirajara Ferreira; Wagner E Matheus; Fabiano A Simões; Ronald F Rejowski; Maria Isabel C Alonso-Vale; Wagner J Fávaro
Journal:  Am J Mens Health       Date:  2016-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.